A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care?

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. doi:10.1001/jamacardio.2021.1437

Continuing Education Information:
Learning Objectives:
1. Define QALY
2. Discuss the cost-effectiveness of dapagliflozin in heart failure

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-264-H01-P
Initial release date: 7/20/21
Expiration date: 7/20/2022
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram